These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
123 related items for PubMed ID: 37081805
1. Fertility recovery after high-dose melphalan containing regimens. Grigg A, Haran H. Leuk Lymphoma; 2023; 64(7):1352-1354. PubMed ID: 37081805 [No Abstract] [Full Text] [Related]
2. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Dreger P, Klöss M, Petersen B, Haferlach T, Löffler H, Loeffler M, Schmitz N. Blood; 1995 Nov 15; 86(10):3970-8. PubMed ID: 7579368 [Abstract] [Full Text] [Related]
3. Fractionated total body irradiation, high-dose melphalan, etoposide, and carboplatin (FTBI-MEC) for autologous stem cell transplantation in children with advanced neuroblastoma and primitive neuroectodermal tumor. Emminger W, Gadner H. Pediatr Hematol Oncol; 1992 Nov 15; 9(2):183-5. PubMed ID: 1356004 [No Abstract] [Full Text] [Related]
4. Visceral leishmaniasis in a patient with relapsed multiple myeloma receiving high-dose melphalan and autologous stem cell transplant. Radujkovic A, Hundemer M, Eisenbach C, Luft T, Penzel R, Goldschmidt H, Ho AD, Bellos F. Leuk Lymphoma; 2014 Dec 15; 55(12):2967-9. PubMed ID: 24707945 [No Abstract] [Full Text] [Related]
5. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group. Blijlevens N, Schwenkglenks M, Bacon P, D'Addio A, Einsele H, Maertens J, Niederwieser D, Rabitsch W, Roosaar A, Ruutu T, Schouten H, Stone R, Vokurka S, Quinn B, McCann S, European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol; 2008 Mar 20; 26(9):1519-25. PubMed ID: 18268357 [Abstract] [Full Text] [Related]
6. Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant. Clark SM, Clemmons AB, Schaack L, Garren J, DeRemer DL, Kota VK. J Oncol Pharm Pract; 2016 Jun 20; 22(3):416-22. PubMed ID: 25956421 [Abstract] [Full Text] [Related]
7. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature]. Adam Z, Krejcí M, Pour L, Stepánková S, Cermáková Z, Voska L, Teplan V, Krivanová A, Hájek R, Mayer J. Vnitr Lek; 2009 Nov 20; 55(11):1089-96. PubMed ID: 20017442 [Abstract] [Full Text] [Related]
8. Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis. Song GY, Jung SH, Lee JJ, Kim JS, Min CK, Kim K, Choi Y, Eom HS, Joo YD, Kim SH, Kwak JY, Kang HJ, Lee JH, Lee HS, Mun YC, Moon JH, Sohn SK, Park SK, Park Y, Shin HJ, Yoon SS. Leuk Lymphoma; 2020 Nov 20; 61(11):2714-2721. PubMed ID: 32580672 [Abstract] [Full Text] [Related]
9. High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. Graham ML, Herndon JE, Casey JR, Chaffee S, Ciocci GH, Krischer JP, Kurtzberg J, Laughlin MJ, Longee DC, Olson JF, Paleologus N, Pennington CN, Friedman HS. J Clin Oncol; 1997 May 20; 15(5):1814-23. PubMed ID: 9164190 [Abstract] [Full Text] [Related]
10. High-dose melphalan with autologous hematopoietic stem cell transplantation for acute myeloid leukemia: results of a retrospective analysis of the Italian Pediatric Group for Bone Marrow Transplantation. Cesaro S, Meloni G, Messina C, Pillon M, Proglia A, Lanino E, Caniggia M, Bagnulo S, Pession A, Locatelli F, Italian Pediatric Group for Bone Marrow Transplantation. Bone Marrow Transplant; 2001 Jul 20; 28(2):131-6. PubMed ID: 11509930 [Abstract] [Full Text] [Related]
11. Impact of chemotherapy on the mobilisation, harvest and economic costs of autologous peripheral stem cell transplantation in patients with multiple myeloma. Jerjis S, Croockewit S, Preijers F, Schaap N, De Witte T. Leuk Lymphoma; 2000 May 20; 37(5-6):551-60. PubMed ID: 11042515 [Abstract] [Full Text] [Related]
12. Dose-intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients. Farag S, Jeker B, Bacher U, Mansouri Taleghani B, Mueller BU, Novak U, Pabst T. Hematol Oncol; 2018 Oct 20; 36(4):671-678. PubMed ID: 30110717 [Abstract] [Full Text] [Related]
13. Effects of cryotherapy on high-dose melphalan-induced oral mucositis in pediatric patients undergoing autologous stem cell transplantation. Kawaguchi K, Umeda K, Takachi T, Ogura T, Horikoshi Y, Saida S, Kato I, Hiramatsu H, Adachi S, Takita J, Watanabe K. Pediatr Blood Cancer; 2020 Sep 20; 67(9):e28495. PubMed ID: 32573946 [Abstract] [Full Text] [Related]
14. Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma. Johnston LJ, Stockerl-Goldstein KE, Hu WW, Negrin RS, Hoppe RT, Blume KG, Horning SJ. Biol Blood Marrow Transplant; 2000 Sep 20; 6(5A):555-62. PubMed ID: 11071261 [Abstract] [Full Text] [Related]
15. Oral glutamine for the prevention of oral mucositis associated with high-dose paclitaxel and melphalan for autologous bone marrow transplantation. Cockerham MB, Weinberger BB, Lerchie SB. Ann Pharmacother; 2000 Mar 20; 34(3):300-3. PubMed ID: 10917373 [Abstract] [Full Text] [Related]
16. High-dose carmustine, etoposide and melphalan ('BEM') with autologous stem cell transplantation: a dose-toxicity study. Ager S, Mahendra P, Richards EM, Bass G, Baglin TP, Marcus RE. Bone Marrow Transplant; 1996 Mar 20; 17(3):335-40. PubMed ID: 8704683 [Abstract] [Full Text] [Related]
17. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. Ayash LJ, Elias A, Schwartz G, Wheeler C, Ibrahim J, Teicher BA, Reich E, Warren D, Lynch C, Richardson P, Schnipper L, Frei E, Antman K. J Clin Oncol; 1996 Nov 20; 14(11):2984-92. PubMed ID: 8918496 [Abstract] [Full Text] [Related]
18. Y90 -Ibritumomab tiuxetan (Y90 -IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05). Voegeli M, Rondeau S, Berardi Vilei S, Lerch E, Wannesson L, Pabst T, Rentschler J, Bargetzi M, Jost L, Ketterer N, Bischof Delaloye A, Ghielmini M. Hematol Oncol; 2017 Dec 20; 35(4):576-583. PubMed ID: 27677906 [Abstract] [Full Text] [Related]
19. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma. Costa LJ, Micallef IN, Inwards DJ, Johnston PB, Porrata LF, Litzow MR, Ansell SM. Br J Haematol; 2008 Oct 20; 143(2):268-73. PubMed ID: 18699848 [Abstract] [Full Text] [Related]
20. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications. Steingrimsdottir H, Gruber A, Björkholm M, Svensson A, Hansson M. Haematologica; 2000 Aug 20; 85(8):832-8. PubMed ID: 10942930 [Abstract] [Full Text] [Related] Page: [Next] [New Search]